These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 24666648)

  • 1. Bexarotene prodrugs: targeting through cleavage by NQO1 (DT-diaphorase).
    Schäfer A; Burstein ES; Olsson R
    Bioorg Med Chem Lett; 2014 Apr; 24(8):1944-7. PubMed ID: 24666648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. INDQ/NO, a bioreductively activated nitric oxide prodrug.
    Sharma K; Iyer A; Sengupta K; Chakrapani H
    Org Lett; 2013 Jun; 15(11):2636-9. PubMed ID: 23659457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and biological evaluation of NAD(P)H: Quinone oxidoreductase (NQO1)-targeted oridonin prodrugs possessing indolequinone moiety for hypoxia-selective activation.
    Xu S; Yao H; Pei L; Hu M; Li D; Qiu Y; Wang G; Wu L; Yao H; Zhu Z; Xu J
    Eur J Med Chem; 2017 May; 132():310-321. PubMed ID: 28395199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of indolequinone mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1): NQO1 inhibition and growth inhibitory activity in human pancreatic MIA PaCa-2 cancer cells.
    Reigan P; Colucci MA; Siegel D; Chilloux A; Moody CJ; Ross D
    Biochemistry; 2007 May; 46(20):5941-50. PubMed ID: 17455910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1 by biochemical, X-ray crystallographic, and mass spectrometric approaches.
    Winski SL; Faig M; Bianchet MA; Siegel D; Swann E; Fung K; Duncan MW; Moody CJ; Amzel LM; Ross D
    Biochemistry; 2001 Dec; 40(50):15135-42. PubMed ID: 11735396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural and synthetic quinones and their reduction by the quinone reductase enzyme NQO1: from synthetic organic chemistry to compounds with anticancer potential.
    Colucci MA; Moody CJ; Couch GD
    Org Biomol Chem; 2008 Feb; 6(4):637-56. PubMed ID: 18264564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioreductive activation of a series of indolequinones by human DT-diaphorase: structure-activity relationships.
    Phillips RM; Naylor MA; Jaffar M; Doughty SW; Everett SA; Breen AG; Choudry GA; Stratford IJ
    J Med Chem; 1999 Oct; 42(20):4071-80. PubMed ID: 10514277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Catalytic properties of NAD(P)H:quinone acceptor oxidoreductase: study involving mouse, rat, human, and mouse-rat chimeric enzymes.
    Chen S; Knox R; Lewis AD; Friedlos F; Workman P; Deng PS; Fung M; Ebenstein D; Wu K; Tsai TM
    Mol Pharmacol; 1995 May; 47(5):934-9. PubMed ID: 7746280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indolequinone antitumour agents: correlation between quinone structure and rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase.
    Newsome JJ; Swann E; Hassani M; Bray KC; Slawin AM; Beall HD; Moody CJ
    Org Biomol Chem; 2007 May; 5(10):1629-40. PubMed ID: 17571194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel silicon-containing analogues of the retinoid agonist bexarotene: syntheses and biological effects on human pluripotent stem cells.
    Bauer JB; Lippert WP; Dörrich S; Tebbe D; Burschka C; Christie VB; Tams DM; Henderson AP; Murray BA; Marder TB; Przyborski SA; Tacke R
    ChemMedChem; 2011 Aug; 6(8):1509-17. PubMed ID: 21726055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical PET Neuroimaging of [11C]Bexarotene.
    Rotstein BH; Placzek MS; Krishnan HS; Pekošak A; Collier TL; Wang C; Liang SH; Burstein ES; Hooker JM; Vasdev N
    Mol Imaging; 2016; 15():. PubMed ID: 27553293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetics of NAD(P)H:quinone oxidoreductase I (NQO1) inhibition by mitomycin C in vitro and in vivo.
    Gustafson DL; Siegel D; Rastatter JC; Merz AL; Parpal JC; Kepa JK; Ross D; Long ME
    J Pharmacol Exp Ther; 2003 Jun; 305(3):1079-86. PubMed ID: 12649308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3-substituted-5-aziridinyl-1-methylindole-4,7-diones as NQO1-directed antitumour agents: mechanism of activation and cytotoxicity in vitro.
    Jaffar M; Phillips RM; Williams KJ; Mrema I; Cole C; Wind NS; Ward TH; Stratford IJ; Patterson AV
    Biochem Pharmacol; 2003 Oct; 66(7):1199-206. PubMed ID: 14505799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical, cytotoxic, and genotoxic effects of ES936, a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1, in cellular systems.
    Dehn DL; Siegel D; Swann E; Moody CJ; Ross D
    Mol Pharmacol; 2003 Sep; 64(3):714-20. PubMed ID: 12920209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The synthesis of a c(RGDyK) targeted SN38 prodrug with an indolequinone structure for bioreductive drug release.
    Huang B; Desai A; Tang S; Thomas TP; Baker JR
    Org Lett; 2010 Apr; 12(7):1384-7. PubMed ID: 20192275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and in vitro evaluation of radioiodinated indolequinones targeting NAD(P)H: quinone oxidoreductase 1 for internal radiation therapy.
    Sasaki J; Sano K; Hagimori M; Yoshikawa M; Maeda M; Mukai T
    Bioorg Med Chem; 2014 Nov; 22(21):6039-46. PubMed ID: 25281270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and biological evaluation of indolequinone phosphoramidate prodrugs targeted to DT-diaphorase.
    Hernick M; Flader C; Borch RF
    J Med Chem; 2002 Aug; 45(16):3540-8. PubMed ID: 12139465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human plasma-mediated hypoxic activation of indolequinone-based naloxone pro-drugs.
    Huang B; Tang S; Desai A; Cheng XM; Kotlyar A; Van Der Spek A; Thomas TP; Baker JR
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5016-20. PubMed ID: 19632838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Advances in studies on selective RXR ligands].
    Mei JH; Wang MW
    Yao Xue Xue Bao; 2005 Apr; 40(4):294-8. PubMed ID: 16011254
    [No Abstract]   [Full Text] [Related]  

  • 20. Possible Molecular Interactions of Bexarotene - A Retinoid Drug and Alzheimer's Aβ Peptide: A Docking Study.
    Mirza Z; Beg MA
    Curr Alzheimer Res; 2017; 14(3):327-334. PubMed ID: 27842487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.